- Home >
- Functional Groups
- Antibody-Based Assays: Developing serological tests to detect host immune responses against pathogens.
- Antigen-Based Assays: Designing diagnostic methods that directly detect pathogen-specific proteins for rapid diagnosis.
- Nucleic Acid-Based Assays: Creating molecular diagnostic techniques to identify and quantify pathogen genetic material with high sensitivity and specificity.
- Cell-Based Assays: Establishing cellular systems to evaluate pathogen detection, infection dynamics, and diagnostic performance.
Development of New Diagnostic Assays
Development of Novel Diagnostic Assays (DNDA) Group: The Development of Novel Diagnostic Assays (DNDA) Group is committed to advancing the frontiers of viral diagnostics by developing innovative, rapid, accurate, affordable, and field-deployable diagnostic technologies for emerging, re-emerging, and endemic viral diseases of public health importance. The group brings together multidisciplinary expertise in molecular virology, biotechnology, immunodiagnostics, genomics, bioengineering, and translational research to design, develop, optimize, validate, and translate next-generation diagnostic platforms that support disease surveillance, outbreak response, and patient care.
The group's research encompasses the entire diagnostic development pipeline—from biomarker discovery and assay design to analytical validation, clinical evaluation, technology transfer, and product translation. Major areas of research include Microfluidic Point-of-Care Testing (PoCT) platforms, RT-LAMP (Reverse Transcription Loop-Mediated Isothermal Amplification) assays, CRISPR-based diagnostics (CRISPR-Dx), SELEX-based protein quantification assays, multiplex real-time RT-PCR assays, serological and immunological assays, lateral flow immunoassay (LFA)-based rapid diagnostic kits, and other next-generation molecular diagnostic technologies. The group also focuses on identifying prognostic biomarkers, host-response signatures, and novel molecular targets that enable early diagnosis, disease severity prediction, and improved clinical management. The DNDA Group develops diagnostic solutions for a wide spectrum of medically important viral pathogens, including SARS-CoV-2, Ebola virus, Nipah virus, Mpox virus, Zika virus, Poliovirus, Dengue virus, Chikungunya virus, Influenza viruses, Crimean–Congo hemorrhagic fever virus (CCHFV), West Nile virus, Human Papillomavirus (HPV), Hepatitis viruses, Measles virus, Rubella virus, Kyasanur Forest Disease virus (KFDV), Chandipura virus, and other arboviruses of national and global public health significance.
Vision: To be a Centre of Excellence in the development of innovative molecular, immunological, and point-of-care diagnostic technologies that enable rapid detection, surveillance, and control of emerging, re-emerging, and endemic viral diseases, thereby strengthening public health preparedness, advancing translational research, and improving patient care through accessible, reliable, high-quality, and affordable diagnostic solutions.
Read More
Read Less
Key Activities
Scientists
Dr. Shyam Sundar Nandi
Scientist-E
Molecular Virology, New Vaccine Development
✉ nandi.shyamsundar@icmr.gov.in
Dr. Alagarasu Kalichamy
Scientist-E
Microbiology, Immunology and Immunogenetics
✉ alagarasu.k@gov.in
Dr. Anita Shete-Aich
Scientist-E
Microbiology, Next generation sequencing, assay developments
✉ sheteaich.a-niv@gov.in
Dr. Tejaswini Mahesh Deshmukh
Scientist-D
Viral Hepatitis, Antiviral Vaccines, Viral Diagnostics & Host–Virus Interactions
✉ deshmukh.t@gov.in
